"An SF-based biotech company is working on a safer, reformulated version of MDMA, better known as molly' or ecstasy,' and we're not tripping when we say they just won FDA approval to begin Phase 1 clinical trials. We have occasionally covered Bay Area medical research into MDMA, the street drug known as ecstasy or molly, and perhaps a little too enthusiastically at that."
"He started researching the molecules in MDMA to formulate a version that was less potent, but more likely to bring on the social and therapeutic effects of the drug. "What if we take this drug and reengineer it to make it not toxic to the brain or minimize its neurotoxic effects?" Obidin said in an SF Business Times interview. "It took decades to develop this in a regulated way.""
Arcadia Medicine, based in San Francisco, received FDA approval to begin Phase 1 clinical trials of a reformulated MDMA called AM-1002. The reformulation aims to retain MDMA's social and therapeutic effects while reducing neurotoxic and cardiac risks. The company attracted $10 million in investment from tech figures including Sam Altman, Fred Ehrsam, and Dylan Field. Founder and CEO Nikita Obidin, a former chemical engineering student, researched MDMA molecules to create a less potent but therapeutically effective variant and described efforts to reengineer the drug to minimize brain toxicity. The program required decades of regulated development.
Read at sfist.com
Unable to calculate read time
Collection
[
|
...
]